Novavax seeks FDA emergency use authorization

Novavax is asking the FDA to authorize its coronavirus vaccine for emergency use in the U.S.

The vaccine is already available for use in at least 170 other countries. If cleared in the U.S., it would provide an alternative to the popular mRNA-based shots from Pfizer and Moderna.

Clinical trial results, published in the New England Journal of Medicine, find two doses of Novavax’s vaccine, given 21 days apart, were safe and highly effective against moderate to severe disease.